{"organizations": [], "uuid": "90dc9fb7d0cc99e1dc43b8351553b6077a149834", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/13", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/05/02/business-wire-qiagen-reports-results-for-first-quarter-2018.html", "country": "US", "domain_rank": 767, "title": "QIAGEN Reports Results for First Quarter 2018", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.075, "site_type": "news", "published": "2018-05-03T00:06:00.000+03:00", "replies_count": 0, "uuid": "90dc9fb7d0cc99e1dc43b8351553b6077a149834"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/05/02/business-wire-qiagen-reports-results-for-first-quarter-2018.html", "ord_in_thread": 0, "title": "QIAGEN Reports Results for First Quarter 2018", "locations": [], "entities": {"persons": [{"name": "natera", "sentiment": "none"}], "locations": [{"name": "netherlands", "sentiment": "none"}, {"name": "frankfurt", "sentiment": "none"}, {"name": "europe", "sentiment": "none"}, {"name": "venlo", "sentiment": "none"}], "organizations": [{"name": "qiagen", "sentiment": "negative"}, {"name": "qiagen n.v.", "sentiment": "none"}, {"name": "nyse", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Net sales of $343.6 million (+12% actual, +6% CER) vs. 5% CER guidance EPS $0.14; adjusted EPS $0.26 ($0.25 CER) vs. ~$0.23-0.24 CER guidance Sample to Insight portfolio building momentum: QIAstat-Dx, a next-generation platform offering syndromic insights for a broad range of applications, launched in Europe QuantiFERON latent TB test growth fueled by geographic expansion and support from new clinical guidelines Natera partnership to expand test menu and value of GeneReader NGS System with a version of the market-leading NIPT assay for GeneReader Robust growth in QIAsymphony system placements toward 2018 goal for more than 2,300 cumulative placements QIAGEN reaffirms 2018 outlook for growth in net sales and adjusted EPS\nVENLO, the Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results of operations for the first quarter, exceeding goals for net sales and adjusted earnings per share while driving global expansion of its Sample to Insight portfolio of molecular testing solutions covering the continuum from basic research to clinical healthcare.\n“Our results for the first quarter have launched QIAGEN into an exciting year of growth for 2018. Our portfolio of Sample to Insight solutions shows good momentum across a broad range of molecular testing needs, and new initiatives offer significant potential for adding to future growth,” said Peer M. Schatz, Chief Executive Officer of QIAGEN N.V.\nPlease find the full press release here\nView source version on businesswire.com : https://www.businesswire.com/news/home/20180502006661/en/\nQIAGEN N.V.\nInvestor Relations:\nJohn Gilardi, +49 2103 29 11711 and +1 240 686 2222\nVice President Corporate Communications and Investor Relations\nJohn.gilardi@qiagen.com\nor\nDr. Sarah Fakih, +49 2103 29 11457\nAssociate Director Investor Relations\nSarah.fakih@qiagen.com\nor\nPublic Relations:\nDr. Thomas Theuringer, +49 2103 29 11826 and +1 240 686 7425\nSenior Director Public Relations and Digital Communications\nor\nRobert Reitze, +49 2103 29 11676\nManager Public Relations\npr@qiagen.com\nor\nwww.twitter.com/qiagen\nwww.facebook.com/QIAGEN\nor\nDownload the QIAGEN Investor Relations App:\nApple\nAndroid\nSource: QIAGEN N.V.", "external_links": ["https://www.businesswire.com/news/home/20180502006661/en/", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.facebook.com%2FQIAGEN&esheet=51800179&lan=en-US&anchor=www.facebook.com%2FQIAGEN&index=3&md5=b312bb00368a47289201f93e9982c20e", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.twitter.com%2Fqiagen&esheet=51800179&lan=en-US&anchor=www.twitter.com%2Fqiagen&index=2&md5=6d0973ae142142a26e59bf06058a20cb", "http://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fitunes.apple.com%2Fus%2Fapp%2Fqiagen-investor-relations%2Fid1170201291%3Fmt%3D8&esheet=51800179&lan=en-US&anchor=Apple&index=4&md5=2c4377124f65b447cff2552acda2458c", "http://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fplay.google.com%2Fstore%2Fapps%2Fdetails%3Fid%3Dcom.theirapp.qiagen%26hl%3Dde&esheet=51800179&lan=en-US&anchor=Android&index=5&md5=7dc9932328a82f5aee9e3ce164caf728", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fcorporate.qiagen.com%2Fnewsroom%2Fpress-releases%2F2018%2F20180502_Q12018_Results%3Fsc_lang%3Den&esheet=51800179&newsitemid=20180502006661&lan=en-US&anchor=here&index=1&md5=627faedb04c0377826d5cf12216c7bc2"], "published": "2018-05-03T00:06:00.000+03:00", "crawled": "2018-05-03T01:49:44.005+03:00", "highlightTitle": ""}